<DOC>
	<DOCNO>NCT03080974</DOCNO>
	<brief_summary>Compare efficacy tolerability irreversible electroporation combination Nivolumab patient locally advanced pancreatic cancer .</brief_summary>
	<brief_title>Immunotherapy Irreversible Electroporation Treatment Advanced Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>Immunotherapy irreversible electroporation treatment advance pancreatic adenocarcinoma . This II study patient undergo irreversible electroporation locally advance pancreatic adenocarcinoma treat nivolumab post-operatively .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>â‰¥ 18 year age Diagnosed stage III pancreatic cancer Tumor measurable Glomerular Filtration Rate &gt; 60 m/L/min/1.73 ( 2 ) Willing able comply protocol requirement Able comprehend sign informed consent participate Participating another clinical trial treatment cancer time screen Are pregnant currently breast feed Have cardiac pacemaker Implantable Cardioverter Defibrillator implant deactivated procedure Have nonremovable implant metal part within 1 cm target lesion Had myocardial infarction within 3 month prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>irreversible electroporation</keyword>
	<keyword>Nivolumab</keyword>
</DOC>